Compare AN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AN | XENE |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 1995 | 2014 |
| Metric | AN | XENE |
|---|---|---|
| Price | $191.53 | $52.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $244.33 | $68.55 |
| AVG Volume (30 Days) | 299.2K | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.71 | N/A |
| EPS | ★ 5.85 | N/A |
| Revenue | ★ $27,631,400,000.00 | $311,000.00 |
| Revenue This Year | $4.32 | N/A |
| Revenue Next Year | $2.89 | $2,496.48 |
| P/E Ratio | $33.17 | ★ N/A |
| Revenue Growth | ★ 3.24 | N/A |
| 52 Week Low | $176.62 | $30.00 |
| 52 Week High | $228.92 | $62.91 |
| Indicator | AN | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 42.63 |
| Support Level | $187.76 | $39.93 |
| Resistance Level | $225.04 | $59.43 |
| Average True Range (ATR) | 4.99 | 1.68 |
| MACD | 0.80 | -0.11 |
| Stochastic Oscillator | 43.25 | 26.46 |
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 240 dealerships, plus 52 collision centers. The firm also has 26 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which has proved to be a smart move.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.